Determination of EBV serostatus prior to kidney transplantation: comparison of VIDAS®, LIAISON® and immunofluorescence assays.
Immunosuppression following solid organ transplantation reduces T cell-mediated immune control of Epstein-Barr Virus (EBV), which may then drive development of post-transplant lymphoproliferative disease. Serology plays a key role in determination of risk of outgrowth of such lesions following transplantation. The study compared the VIDAS(®) (bioMérieux) and LIAISON(®) (DiaSorin) enzyme immunoassays (EIAs) and immunofluorescence assays (IFA; MBL-Bion) in the kidney transplantation setting. Sera from 100 live kidney donors [51 males; age range 20-82 years (mean 51.2 years)] and 100 cadaveric kidney recipients [70 males; age range 17-77 years (mean 51.0 years)] were tested. Overall proportional agreement ranged from 96% to 100% for VIDAS(®) and LIAISON(®). Sensitivity ranged from 91% to 100% and 92% to 100% for VIDAS(®)/IFA and LIAISON(®)/IFA, respectively. The VIDAS(®) and LIAISON(®) approaches gave similar results. Such automated random access EIAs are well suited to busy clinical virology laboratories and rapid determination of donor and recipient EBV serostatus prior to transplantation.